Deininger, M. W., Hodgson, J. G., Shah, N. P., Cortes, J. E., Kim, D., Nicolini, F. E., . . . Branford, S. (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood.
Citação norma ChicagoDeininger, Michael W., et al. "Compound Mutations in BCR-ABL1 Are Not Major Drivers of Primary or Secondary Resistance to Ponatinib in CP-CML Patients." Blood 2016.
Citação norma MLADeininger, Michael W., et al. "Compound Mutations in BCR-ABL1 Are Not Major Drivers of Primary or Secondary Resistance to Ponatinib in CP-CML Patients." Blood 2016.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.